Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.

about

Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.

Item

http://www.wikidata.org/entity/Q39005718

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Comparative risk of failure of ...... tients with a high viral load.

@en

Comparative risk of failure of ...... tients with a high viral load.

@nl

type

Item

label

Comparative risk of failure of ...... tients with a high viral load.

@en

Comparative risk of failure of ...... tients with a high viral load.

@nl

prefLabel

Comparative risk of failure of ...... tients with a high viral load.

@en

Comparative risk of failure of ...... tients with a high viral load.

@nl

P1476

Comparative risk of failure of ...... tients with a high viral load.

@en

P2093

A Cheret

http://www.w3.org/2001/XMLSchema#string

C Allavena

http://www.w3.org/2001/XMLSchema#string

C Chirouze

http://www.w3.org/2001/XMLSchema#string

D Rey

http://www.w3.org/2001/XMLSchema#string

Dat'AIDS Study group

http://www.w3.org/2001/XMLSchema#string

F Bani-Sadr

http://www.w3.org/2001/XMLSchema#string

L Cotte

http://www.w3.org/2001/XMLSchema#string

L Cuzin

http://www.w3.org/2001/XMLSchema#string

P Pugliese

http://www.w3.org/2001/XMLSchema#string

P2860

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

Variable selection for propensity score models

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Constructing inverse probability weights for marginal structural models.

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

Virologic efficacy of boosted double versus boosted single protease inhibitor therapy.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

P304

380-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HIV.12306

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

André Cabié

Philippe Flandre

Christine Katlama

P577

2015-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27093565

http://www.w3.org/2001/XMLSchema#string

P921

viral load